AU Patent

AU2019348011A1 — Degradation of FAK or FAK and ALK by conjugation of FAK and ALK inhibitors with E3 ligase ligands and methods of use

Assigned to Dana Farber Cancer Institute Inc · Expires 2021-02-11 · 5y expired

What this patent protects

Disclosed are bifunctional compounds (degraders) that target FAK or FAK and ALK for degradation. Also disclosed are pharmaceutical compositions containing the degraders and methods of using the compounds to treat disease.

USPTO Abstract

Disclosed are bifunctional compounds (degraders) that target FAK or FAK and ALK for degradation. Also disclosed are pharmaceutical compositions containing the degraders and methods of using the compounds to treat disease.

Drugs covered by this patent

Patent Metadata

Patent number: AU2019348011A1
Jurisdiction: AU
Classification: —
Expires: 2021-02-11
Drug substance claim: No
Drug product claim: No
Assignee: Dana Farber Cancer Institute Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.